8-K: Plus Therapeutics Announces Positive Clinical Trial Results and Second Quarter 2024 Financials

Plus Therapeutics reported positive interim data for its ReSPECT-LM Phase 1 trial and topline results for its CNSide diagnostic test, alongside its second quarter 2024 financial results.

Summary

• Plus Therapeutics announced its financial results for the second quarter ending June 30, 2024, and provided updates on its clinical programs.
• The company presented positive interim data from its ReSPECT-LM Phase 1 study, showing that Rhenium (186Re) Obisbemeda was safe and well-tolerated in the first 4 dosing cohorts with a median overall survival of 12 months and 8 of 16 patients still alive.
• Topline results from the FORESEE trial demonstrated that the CNSide diagnostic platform met its primary clinical endpoint, aiding clinical decision-making in over 90% of provider decisions and informing therapy selection in 24% of decisions.
• The CNSide test also improved tumor cell detection in leptomeningeal metastases (LM) patients compared to cytology, with 80% detection versus 29% in matched samples.
• The company received a $3.3 million grant payment from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the clinical development of Rhenium (186Re) Obisbemeda for LM.
• Plus Therapeutics' cash and investments balance was $8.4 million at June 30, 2024, compared to $8.6 million at December 31, 2023.
• The company recognized $3.0 million in grant revenue in the first half of 2024, compared to $2.4 million in the same period of 2023.
• Total operating loss for the first half of 2024 was $7.0 million, compared to $6.2 million in the same period of 2023, primarily due to increased spending on the ReSPECT-LM trial.
• Net loss for the first half of 2024 was $6.2 million, or $(1.15) per basic share, compared to a net loss of $6.3 million, or $(2.60) per basic share, for the same period the prior year.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical trial results and increased grant revenue, although the company is still operating at a loss. The positive clinical data and grant funding are encouraging, but the company's financial position requires careful monitoring.

Positives

• The ReSPECT-LM Phase 1 study showed promising safety and tolerability results for Rhenium (186Re) Obisbemeda, with a median overall survival of 12 months.
• The CNSide diagnostic platform demonstrated its effectiveness in aiding clinical decision-making and improving tumor cell detection.
• The $3.3 million grant from CPRIT provides financial support for the development of Rhenium (186Re) Obisbemeda.
• The company's grant revenue increased to $3.0 million in the first half of 2024, compared to $2.4 million in the same period of 2023.
• The company is on track to complete the single administration ReSPECT-LM Phase 1 trial soon, expand to multiple doses, and move to Phase 2.

Negatives

• The company's cash and investments balance decreased slightly from $8.6 million at the end of 2023 to $8.4 million at the end of the second quarter of 2024.
• The total operating loss for the first half of 2024 increased to $7.0 million, compared to $6.2 million in the same period of 2023.
• The net loss for the first half of 2024 was $6.2 million, although the loss per share improved from $(2.60) to $(1.15).

Risks

• The company is in the early stages of developing its product candidates and therapies, which carries inherent risks.
• Clinical trial results may not always be positive or lead to regulatory approvals.
• The company's ability to raise additional capital is crucial for its continued operations and development.
• There are risks associated with laws, regulatory requirements, market conditions, and competition in the cancer diagnostics and therapeutics field.
• The company faces risks related to protecting its intellectual property and potential security breaches.

Future Outlook

The company plans to complete the single administration ReSPECT-LM Phase 1 trial, expand to multiple doses, and move to Phase 2. They also plan to initiate a Phase 1 multiple administration trial and obtain IND approval for a Phase 1/2 trial of Rhenium (186Re) Obisbemeda via convection enhanced delivery (CED). Presentations are planned at upcoming medical conferences.

Management Comments

• Plus lead investigational drug Rhenium (186Re) Obisbemeda continues to show safety and promising signs of efficacy after a single administration in patients with LM, said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer.
• We are on track to complete the single administration ReSPECT-LM Phase 1 trial soon, expand to multiple doses, and move to Phase 2 funded by our existing CPRIT award.

Industry Context

This announcement is relevant to the broader pharmaceutical industry, particularly in the areas of radiotherapeutics and cancer diagnostics. The positive clinical trial results for Rhenium (186Re) Obisbemeda and the CNSide diagnostic platform position Plus Therapeutics as a potential player in the treatment of central nervous system cancers.

Comparison to Industry Standards

• The reported median overall survival of 12 months in the ReSPECT-LM Phase 1 trial is a positive signal, but further data is needed to compare it to standard treatments for leptomeningeal metastases.
• The CNSide diagnostic test's 80% tumor cell detection rate is significantly higher than the 29% rate achieved by cytology, suggesting a potential improvement in diagnostic accuracy.
• Companies like Northwest Biotherapeutics and Kazia Therapeutics are also developing therapies for brain cancers, and the results from Plus Therapeutics will be closely watched by investors and competitors.
• The $3.3 million grant from CPRIT is a significant non-dilutive funding source, which is a positive sign for the company's financial health compared to companies that rely solely on equity financing.

Stakeholder Impact

• Shareholders may view the positive clinical trial results and increased grant revenue favorably.
• Employees may be encouraged by the progress of the company's clinical programs.
• Patients with central nervous system cancers may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Complete the single administration ReSPECT-LM Phase 1 trial and determine the recommended Phase 2 dose.
• Initiate the ReSPECT-LM Phase 1 multiple administration trial.
• Obtain IND approval for a Phase 1/2 trial of Rhenium (186Re) Obisbemeda via convection enhanced delivery (CED).
• Presentations at the Congress of Neurological Surgeons (CNS) Annual Conference (September 28-October 2, 2024) and the Society for Neuro-Oncology (SNO) Annual Conference (November 22-26, 2024).

Key Dates

Keywords

Rhenium (186Re) Obisbemeda, CNSide, Leptomeningeal Metastases, Radiotherapeutics, Clinical Trials, Cancer, Neuro-Oncology, Diagnostics, Phase 1, Phase 2, Drug Development